

Amphastar Pharmaceuticals, Inc.  
 Form 3  
 June 24, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â Purchase Marilyn J.</p> <p>(Last) (First) (Middle)</p> <p>C/O AMPHASTAR                  PHARMACEUTICALS,                  INC.,Â 11570 6TH STREET</p> <p>(Street)</p> <p>RANCHO                  CUCAMONGA,Â CAÂ 91730</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>06/24/2014</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Amphastar Pharmaceuticals, Inc. [AMPH]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p>___ Director ___ 10% Owner                  ___X___ Officer ___ Other                  (give title below) (specify below)                  Corp. Exec. VP of Operations</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p>___X___ Form filed by One Reporting Person                  ___ Form filed by More than One Reporting Person</p>
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	16,859 <sup>(1)</sup>	D	Â
Common Stock	2,757 <sup>(2)</sup>	D	Â
Common Stock	11,437 <sup>(3)</sup>	D	Â
Common Stock	17,605 <sup>(4)</sup>	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: Amphastar Pharmaceuticals, Inc. - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	Â <u>(5)</u>	07/29/2014	Common Stock	15,000	\$ 14.8	D	Â
Stock Option (Right to Buy)	Â <u>(5)</u>	05/15/2015	Common Stock	28,000	\$ 14.8	D	Â
Stock Option (Right to Buy)	Â <u>(5)</u>	05/10/2016	Common Stock	15,000	\$ 20	D	Â
Stock Option (Right to Buy)	Â <u>(5)</u>	12/03/2017	Common Stock	25,000	\$ 31.02	D	Â
Stock Option (Right to Buy)	Â <u>(5)</u>	08/18/2018	Common Stock	25,000	\$ 35.32	D	Â
Stock Option (Right to Buy)	Â <u>(6)</u>	08/02/2019	Common Stock	25,000	\$ 20.26	D	Â
Stock Option (Right to Buy)	Â <u>(7)</u>	09/28/2020	Common Stock	30,000	\$ 11.79	D	Â
Stock Option (Right to Buy)	Â <u>(8)</u>	10/03/2021	Common Stock	15,789	\$ 15.23	D	Â
Stock Option (Right to Buy)	Â <u>(9)</u>	07/13/2022	Common Stock	47,877	\$ 10.46	D	Â
Stock Option (Right to Buy)	Â <u>(10)</u>	09/28/2022	Common Stock	8,315	\$ 10.48	D	Â
Stock Option (Right to Buy)	Â <u>(11)</u>	07/05/2023	Common Stock	32,081	\$ 10.93	D	Â
Stock Option (Right to Buy)	Â <u>(12)</u>	03/27/2024	Common Stock	25,445	\$ 14.4	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Purchase Marilyn J. C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730	Â	Â	Â Corp. Exec. VP of Operations	Â

## Signatures

/s/Marilyn J. Purchase, by Power of  
Attorney

06/24/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This includes 16,044 shares held by the Purchase Family Trust (the "Trust"). The reporting person and her husband are the sole co-trustees of the Trust, and they share voting and investment power.
- (2) This represents the remaining amount of deferred stock units that were granted on 10/3/2011. The original amount was 5,515. This vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (3) This represents deferred stock units that were granted on 7/5/2013 and vest over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (4) This represents deferred stock units that were granted on 3/27/2014 and vest over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (5) This option is fully vested and exercisable.
- (6) This option was granted on 8/2/2009 and vests over 5 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (7) This option was granted on 9/28/2010 and vests over 5 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (8) This option was granted on 10/3/2011 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (9) This option was granted on 7/13/2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (10) This option was granted on 9/28/2012 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (11) This option was granted on 7/5/2013 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.
- (12) This option was granted on 3/27/2014 and vests over 4 years in equal annual installments commencing on the first anniversary of the grant date, subject to the reporting person's continued employment with or service to the Issuer or subsidiary thereof through the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.